What we're reading, January 28, 2016: Massachusetts' attorney general is threatening to sue Gilead Sciences over the high prices of its hepatitis C drugs; Anthem reports losses on Obamacare health plans; and consumers are satisfied with health coverage and limited networks.
In Massachusetts, the attorney general has warned Gilead Sciences that its high prices for Sovaldi and Harvoni may be illegal and violate the state’s law for fair trade practice. The Attorney general is not looking to sue the drugmaker for larger rebates or discounts, as others have done in the past, but for overpricing its products and violating consumer protection law, according to The Boston Globe.
UnitedHealth is not the only insurer feeling the pain from Affordable Care Act health plans. Now Anthem has announced that exchange plans caused the company to miss analyst expectations for fourth quarter earnings, reported Reuters. Anthem had enrolled 30% fewer beneficiaries than expected, which made the costs of running the business too high. However, Anthem CEO Joseph Swedish said enrollment data for 2016 so far looks a little better.
A new survey from Kaiser Family Foundation found that a majority of consumers don’t mind limited networks of doctors and hospitals to restrain prices and were satisfied with their coverage and the cost. However, people without insurance were less pleased and usually did not have coverage because they found it too expensive. In addition, healthcare is no longer a top priority for voters in the upcoming presidential election.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More